Core Insights - Bio-Techne Corporation will present at multiple investor conferences in November 2024, including the UBS Global Healthcare Conference, Stifel 2024 Healthcare Conference, and Stephens NASH 2024 Conference [1] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [2]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIO.B New York Stock Exchange For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTIO ...

Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company’s GAAP EPS was $23.34, up 541.2% from ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Tycho Pe ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.03%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.12 per share when it actually produced earnings of $3.11, delivering a surprise of 46. ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...

Financial Performance - Bio-Techne Corporation reported first quarter fiscal 2025 net sales of $289.5 million, representing a 5% increase compared to the same quarter last year, with organic revenue growth of 4% [2][7] - GAAP earnings per share (EPS) decreased to $0.21 from $0.31 in the prior year, while adjusted EPS increased to $0.42 from $0.41 [2][8] - GAAP operating income fell 28% to $40.0 million, resulting in a GAAP operating margin of 13.8%, down from 20.2% in the same quarter last year [7][8] Segment Performance - The Protein Sciences segment reported net sales of $204.5 million, remaining flat compared to $204.7 million in the same quarter last year, with an organic growth of 1% [9] - The Diagnostics and Spatial Biology segment achieved net sales of $83.2 million, a 14% increase from $72.8 million in the prior year, with organic revenue growth also at 14% [10] Management Commentary - The CEO highlighted strong execution in the Diagnostics & Spatial Biology segment and robust growth in the cell and gene therapy business, particularly in GMP reagent offerings [5] - The company expressed confidence in the recovery of the biotech end market, supported by favorable funding dynamics [5] Cash Flow and Financial Position - Cash and cash equivalents at the end of the quarter were $187.5 million, up from $151.8 million at the beginning of the period [31] - The company reported net cash provided by operating activities of $63.9 million, compared to $59.4 million in the same quarter last year [31]

With the third-quarter earnings season in full swing, it's going to be a pivotal week for numerous firms within the medical device sector. The latest Earnings Preview report indicates strong earnings and revenue growth within the Medical sector. The projected top and bottom-line improvements can be attributed to sustained demand for medical products and services, and favorable pricing strategies, which are likely to offset the shortcomings generated from worldwide geopolitical issues, high-interest expense ...